GlassScriptPhysician profile
Sahil Parag
NPI 1629605001
$1,608.24
in general payments reported to CMS, 2019-2025
20 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $296 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,608.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $367.23 | 2024-2025 | Lupkynis |
| Ardelyx, INC. | $217.32 | 2025 | Xphozah 30 Mg, Ibsrela |
| Akebia Therapeutics INC | $185.20 | 2025 | Vafseo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.99 | 2025 | Jardiance |
| Outset Medical INC | $100.82 | 2024 | |
| Novartis Pharmaceuticals Corporation | $91.40 | 2025 | |
| Alnylam Pharmaceuticals INC. | $73.00 | 2025 | Oxlumo |
| Ibsa Pharma INC. | $70.11 | 2025 | Tirosint, Licart, Flector |
| Sumitomo Pharma America, INC. | $63.04 | 2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $49.41 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $43.69 | 2025 | Jynarque, Voyxact |
| Idorsia Pharmaceuticals US INC | $38.76 | 2025 | Tryvio |
| Mallinckrodt Hospital Products INC. | $34.35 | 2025 | Acthar |
| Ascendis Pharma Endocrinology INC | $29.94 | 2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $28.82 | 2025 | Farxiga |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $27.34 | 2025 | Tarpeyo |
| Lilly USA, LLC | $24.87 | 2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $22.30 | 2025 | Wegovy |
| Exact Sciences Corporation | $17.50 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $17.15 | 2025 | Otezla, Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sahil Parag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.